JANAGLIP 100MG 7 F.C. TAB

ABOUT SITAGLIPTIN ANTIDIABETIC AGENT ORAL HYPOGLYCAEMIC MECHANISM OF ACTION OF SITAGLIPTIN VILDAGLIPTIN IS A DIPEPTIDYLPEPTIDASE-4 (DPP-4) INHIBITOR THAT IMPROVES GLYCAEMIC CONTROL BY PREVENTING DPP-4 FROM INACTIVATING THE INCRETIN HORMONES GLUCAGON-LIKE PEPTIDE-1 AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE THUS PROLONGING INCRETIN ACTIVITY IN RESPONSE TO INGESTION OF NUTRIENTS. THIS INCREASES INSULIN SENSITIVITY DECREASES GLUCAGON SECRETION AND IMPROVES ?-CELL FUNCTION. INDICATIONS FOR SITAGLIPTIN TYPE 2 DIABETES MELLITUS INTERACTIONS FOR SITAGLIPTIN DIGOXIN: INCREASE CONCENTRATION OF DIGOXIN INCREASED RISK OF HYPOGLYCAEMIA WHEN USED WITH OTHER ANTI-DIABETIC AGENTS